I had the privilege to attend a neuroscience seminar where Dr. Yanan Chen spoke about her research on Pelizaeus-Merzbacher Disease and oligodendrocyte survival. Due to my interest regarding the topic of hypomyelinated neuronal diseases, I made the decision to research and learn more about it and discuss my findings. Because there is little to be known about the direct causes of Multiple Sclerosis and, therefore, finding a cure, I find it interesting to learn about other similar diseases, such as PMD, that affect the myelination process. Dr. Chen’s research and other studies, however, are changing this by showing possible solutions or resistance therapies to these diseases.
Before presenting her findings and research during the NEUR 300 seminar, Dr. Yanan Chen presented a study that shows how Pelizaeus-Merzbacher Disease negatively impacts the survival of oligodendrocytes and how integrated stress response inhibitors can aid in preserving the oligodendrocytes’ survival, despite the effects of PMD. They focused mainly on the male PMD mouse model Jimpy to “determine the impact of integrated stress response (ISR) on the oligodendrocyte response to mutant PLP expression” (Chen 2025). The study found that when the ISR-triggering eukaryotic initiation factor (eIF) 2α kinase was successfully inactivated, this process correlates with the survival of oligodendrocytes and myelination in the CNS.
I became interested in this particular study because, when doing my own research, I found that I knew from previous research and courses at Loyola University Chicago that Multiple Sclerosis was a similar disease in the sense that it involves hypomyelination of axons, and therefore, I was wondering why there was not a cure yet found for either disease. I found a supplementary study by Doghish, Elazazy, Mohamed, Mansour, Ghanem et al. (2023), that describes how miRNAs could possibly play a significant role in Multiple Sclerosis "pathogenesis, diagnosis, and therapeutic resistance", and I was immediately intrigued (Doghish 2023). The study revealed that the diagnosis of Multiple Sclerosis was difficult “due to the lack of disease-specific biomarkers” and therefore, depends on ruling out numerous disabilities (Doghish 2023). Because of this, the researchers hope to further study “biological features of miRNAs in MS and explore their potential as a therapeutic target” (Doghish 2023).
When reviewed as a whole, these investigations only provide a broad and hopeful conclusion to the problem, however, more research and findings must be done to provide a convincing conclusion overall. While Dr. Chen showed that the ISR-triggering eukaryotic initiation factor (eIF) 2α kinase was completely non-functioning, the survival of the oligodendrocytes and myelination of the CNS increased, Doghish, Elazazy, Mohamed, Mansour, Ghanem et al. (2023) showed that there is much to be revealed in the future regarding the future of miRNAs in multiple aspects of MS. These new discoveries and sciences may be used to treat not only PMD and MS, but also, provide a different approach to diagnosing and treating diseases involving the structure and functionality of the CNS. Together, these investigations reveal a bridge between neurological understandings and discussion, and therefore, provide hope for the future of curing uncurable diseases.
References:
Chen, Y., Kunjamma, R.B., Lin, K. et al. Integrated stress response inhibition prolongs the lifespan of a Pelizaeus-Merzbacher disease mouse model by increasing oligodendrocyte survival. Nat Commun (2025). https://doi.org/10.1038/s41467- 025-68045-0
Doghish, Ahmed S, et al. “The Role of MiRNAs in Multiple Sclerosis Pathogenesis, Diagnosis, and Therapeutic Resistance.” Pathology, Research and Practice, vol. 251, 1 Nov. 2023, pp. 154880–154880, https://doi.org/10.1016/j.prp.2023.154880. Accessed 19 Apr. 2024.